VRTX Jan 2025 360.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 09:35AM EDT. Market open.
| Previous Close | 104.47 |
| Open | 104.47 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 360.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 104.47 - 104.47 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Business WireVertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
BOSTON, June 07, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), also known in the European Union and in the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 47th European Cystic Fibrosis Conference held June 5-8, 2024, in Glasgow, Scotland.
GuruFocus.comInsider Sale: EVP & CFO Charles F. Wagner Jr. Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
On June 3, 2024, Charles F. Wagner Jr., Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 3,250 shares of the company.
Investor's Business DailyDow Jones Futures Fall As Growth Fears Mount; 7 Stocks Near Buy Points
The stock market was mixed Monday, but once again closed strong. Nvidia jumped while Meta and Spotify are stocks near buy points.
© 2024 Yahoo. All rights reserved.